Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410316 | 0.87 | MTNR1A (0.37) | MTNR1ACHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL395587 | 0.84 | CHRM2 (0.33) | CHRM2CHRM4CHRM5CHRM3CYP19A1 | |
| SCHEMBL5402113 | 0.81 | CHRM2 (0.36) | MTNR1ACHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL395864 | 0.80 | ELOVL1 (0.30) | ELOVL1 | |
| SCHEMBL5402690 | 0.79 | POLB (0.35) | MTNR1ACHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL84293 | 0.79 | MTNR1A (0.36) | MTNR1ACHRM2CHRM4CHRM5CHRM3 | |
| SCHEMBL10073990 | 0.77 | ELOVL1 (0.36) | ELOVL1 | |
| SCHEMBL5423533 | 0.77 | CYP1A2 (0.38) | CYP1A2CYP3A4CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL437895 | 0.77 | POLB (0.39) | ELOVL1 | |
| SCHEMBL5410692 | 0.75 | CHRNA7 (0.41) | CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088914-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8101753-B2 | Production method of pyrimidine compounds | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-01-24 | — | — | US | disclosed |
| EP-1809610-B1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | SUMITOMO CHEMICAL CO (JP) | 2011-08-24 | — | — | EP | disclosed |
| US-20080039445-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1809610-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | Sumitomo Chemical Company, Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006051891-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088914-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | DPYD, DHFR, DHODH | MTNR1A 4745/4885CHRM2 1125/4885CHRM4 1403/4885 |
| US-20080039445-A1 | PRODUCTION METHOD OF PYRIMIDINE COMPOUNDS | DPYD, DHFR, DHODH | MTNR1A 4745/4885CHRM2 1125/4885CHRM4 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.